Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Thomas Chatzikonstantinou, Andreas Agathangelidis, Persefoni Talimtzi, Stamatia Laidou, Eva Minga, Athanasios Roussos, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Fanny Baran-Marszak, Csaba Bödör, Francesc Bosch Albareda, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Thalia Karamanli, Eliana Konstantinou, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Tamas Laszlo, Vincent Levy, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Eugenia Mpalaoura, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Karla Plevova, Sarka Pospisilova, Anna Puiggros, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Angel Serna, Martin Simkovic, Lukas Smolej, Niki Stavrogianni, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Lydia Scarfo, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2025) 146 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2025-2120

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

Patricia Fernández-Guzmán, Iñaki Salvador Corres, Hristo Iliev Iliev, Gemma Pujadas Rovira, Víctor Navarro Garces, Anna Aguilera Romero, Josep Castellvi, Daniel Medina-Gil, Maite Erguin, Sofia Mallorquí-Alcalá, Angel Serna, Pau Abrisqueta, Francesc Bosch Albareda, Marta Crespo

Blood (2025) 146 (Supplement 1): 5656.

https://doi.org/10.1182/blood-2025-5656

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Intermediate and high-risk clonal hematopoiesis in germline predisposition families

Sandra Novoa Jáuregui, Sara Torres-Esquius, Maria Gabarrós Subirà, Pamela Acha, Francisco Beas, Ana Maria Garrido, Marc Bosch-Schips, Claudia Pellin Jou, Adriana Oños, Sílvia Saumell Tutusaus, Ana Perez Gonzalez, Adoracion Blanco, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2025-2058

Published: 2025

Journal Articles

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Sara Torres-Esquius, Maria Gabarros-Subira, Maria Eugenia Rivero, Guillermo Ramil López, Lucia García Mañó, Felix Lopez, Concepción Fernandez, Francesca Guijarro, Marina Díaz-Beyá, Marta Pratcorona Canela, Pamela Acha, Sandra Novoa Jáuregui, Esperanza Tuset, Laura Palomo, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4998.

https://doi.org/10.1182/blood-2025-4998

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

Sergi Camarillas, Samantha Feijoo, Anna Aguilera Romero, Corrado Benevolo Savelli, Víctor Navarro Garces, Andreu Vilaseca, Maria Landwehr, Helena Ariño, Marina Serra, Marc Bosch-Schips, Cristina García Herce, Cecilia Carpio, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba, Gloria Iacoboni

Blood (2025) 146 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2025-5498

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Beyond TP53: Molecular IPSS-genes multihit status revisited

Blood (2025) 146 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2025-2090

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Thomas Chatzikonstantinou, Sevasti Konstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Francesco Angotzi, Marcello Bradaschia, Sophia Chatzileontiadou, Caterina Chessa, Marta Crespo, Maria Dimou, Alessandro Gozzetti, Ritu Gupta, Eliana Konstantinou, Andreas Epameinondas Koumpis, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Roberta Murru, Leila Perobelli, Lata Rani, Ilaria Romano, Gian Matteo Rigolin, Angel Serna, Andrea Visentin, Candida Vitale, George Vrachiolias, Celso Arrais-Rodrigues, Rodrigo Santucci da Silva, Carlos Chiattone, Francesc Bosch Albareda, Anastasia Chatzidimitriou, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Eleftheria Hatzimichael, Yair Herishanu, Ioannis Kotsianidis, Panagiotis Panagiotidis, Maria Papaioannou, Davide Rossi, Niki Stavrogianni, Livio Trentin, Theodoros Vassilakopoulos, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2025-5665

Published: 2025

Journal Articles

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Marcello Bradaschia, Alessandro Cellini, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Carlos Chiattone, Rosa Collado, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Rocio Garcia-Serra, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Ozren Jaksic, Maria Kislova, Eliana Konstantinou, Sevasti Konstantinou, Maya Koren Michowitz, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Luca Laurenti, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Rocio Nieves Salgado Sanchez, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Leila Perobelli, Sarka Pospisilova, Anna Puiggros, Claus Rainer, Sergio Ramos, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Rodrigo Santucci, Angel Serna, Marina Siakantaris, Talita Silveira, Paolo Sportoletti, Niki Stavrogianni, Annamaria Tomasso, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Munci Yagci, Seyma Yildiz, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2025-5664

Published: 2025

Journal Articles

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Blood (2025) 146 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2025-1962

Published: 2025

Journal Articles

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Blood (2025) 146 (Supplement 1): 782.

https://doi.org/10.1182/blood-2025-782

Published: 2025

Journal Articles

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Guillermo Orti, Cecilia Carpio, Gloria Iacoboni, Lorenzo Carita, Samantha Feijoo, Corrado Benevolo Savelli, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Víctor Navarro Garces, Sergi Cantenys-Molina, Monica Martinez, Miguel Gonzalez, Marta Crespo, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba

Blood (2025) 146 (Supplement 1): 2365.

https://doi.org/10.1182/blood-2025-2365

Published: 2025

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Intermediate and high-risk clonal hematopoiesis in germline predisposition families

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Beyond TP53: Molecular IPSS-genes multihit status revisited

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only